Abstract
Gene modification of eukaryotic cells by electroporation is a widely used method to express selected genes in a defined cell population for various purposes, like gene correction or production of therapeutics. Here, we describe the generation of a cell-based tumor vaccine via fourfold transient gene modification of a human renal cell carcinoma (RCC) cell line for high expression of CD80, CD154, GM-CSF, and IL-7 by use of MIDGE® vectors. The two co-stimulatory molecules CD80 and CD154 are expressed at the cell surface, whereas the two cytokines GM-CSF and IL-7 are secreted yielding cells with enhanced immunological properties. These fourfold gene-modified cells have been used as a cell-based tumor vaccine for the treatment of RCC.
MIDGE® and dSLIM® are registered trademarks of MOLOGEN AG, Berlin, Germany.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Schakowski F et al (2001) A novel minimal-size vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA. Mol Ther 3:793–800
Moreno S et al (2004) DNA immunisation with minimalistic expression constructs. Vaccine 22:1709–1716
Schmidt M, Volz B, Wittig B (2005) MIDGE Vectors and dSLIM Immunomodulators: DNA-based Molecules for Gene Therapeutic Strategies. In: Knäblein J, Müller RH (eds) Modern Biopharmaceutical. WILEY-VCH Verlag, Weinheim, pp 1–29
Schakowski F et al (2007) Minimal size MIDGE vectors improve transgene expression in vivo. In Vivo 21:17–23
Endmann A et al (2010) Immune response induced by a linear DNA vector: influence of dose, formulation and route of injection. Vaccine 28:3642–369
Kobelt D (2014) Preclinical study on combined chemo- and nonviral gene therapy for sensitization of melanoma using a human TNF-alpha expressing MIDGE DNA vector. Mol Oncol 8:609–619
Keenan BP, Jaffee EM (2012) Whole cell vaccines–past progress and future strategies. Semin Oncol 39:276–286
Schendel DJ et al (2000) Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse. Gene Ther 7:2007–2014
Johnson BD et al (2005) Neuroblastoma cells transiently transfected to simultaneously express the co-stimulatory molecules CD54, CD80, CD86, and CD137L generate antitumor immunity in mice. J Immunother 28:449–460
Dzojic H et al (2006) Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model. Prostate 66:831–838
Loskog A, Totterman TH (2007) CD40L - a multipotent molecule for tumor therapy. Endocr Metab Immune Disord Drug Targets 7:23–28
Ruybal P et al (2008) Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40. Vaccine 26:697–705
Zhan Y et al (2011) GM-CSF increases cross-presentation and CD103 expression by mouse CD8(+) spleen dendritic cells. Eur J Immunol 41:2585–2595
Morre M, Beq S (2012) Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival. Target Oncol 7:55–68
Schmidt M et al (2006) Cytokine and Ig-production by CG-containing sequences with phosphorodiester backbone and dumbbell-shape. Allergy 61:56–63
Kapp K et al (2014) Genuine immunomodulation with dslim. Mol Ther Nucleic Acids 3:e170
Schmidt M et al (2015) Design and structural requirements of the potent and safe TLR-9agonistic immunomodulator MGN1703. Nucleic Acid Ther (in press)
Schmoll HJ et al (2014) Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol, Epub ahead of print
Wittig B et al (2015) MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside. Crit Rev Oncol Hematol 94:31–44
Grünwald V et al (2014) Final results of patients with metastatic renal cell carcinoma treated with MGN1601 in the ASET study. J Clin Oncol 32(15 suppl), e15590
Acknowledgements
We thank Florian Sack for expert review of the manuscript.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Schmidt, M., Volz, B., Großmann, P., Heinrich, K., Wittig, B. (2015). MIDGE Technology for the Production of a Fourfold Gene-Modified, Allogenic Cell-Based Vaccine for Cancer Therapy. In: Walther, W., Stein, U. (eds) Gene Therapy of Solid Cancers. Methods in Molecular Biology, vol 1317. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2727-2_3
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2727-2_3
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2726-5
Online ISBN: 978-1-4939-2727-2
eBook Packages: Springer Protocols